» Articles » PMID: 34141068

Massively Parallel Optimization of the Linker Domain in Small Molecule Dimers Targeting a Toxic R(CUG) Repeat Expansion

Overview
Specialty Chemistry
Date 2021 Jun 18
PMID 34141068
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

RNA contributes to disease pathobiology and is an important therapeutic target. The downstream biology of disease-causing RNAs can be short-circuited with small molecules that recognize structured regions. The discovery and optimization of small molecules interacting with RNA is, however, challenging. Herein, we demonstrate a massively parallel one-bead-one-compound methodology, employed to optimize the linker region of a dimeric compound that binds the toxic r(CUG) repeat expansion [r(CUG)] causative of myotonic dystrophy type 1 (DM1). Indeed, affinity selection on a 331,776-member library allowed the discovery of a compound with enhanced potency both in vitro (10-fold) and in DM1-patient-derived myotubes (5-fold). Molecular dynamics simulations revealed additional interactions between the optimized linker and the RNA, resulting in ca. 10 kcal/mol lower binding free energy. The compound was conjugated to a cleavage module, which directly cleaved the transcript harboring the r(CUG) and alleviated disease-associated defects.

Citing Articles

Experimental and computational investigations of RNA duplexes containing N7-regioisomers of adenosine and LNA-adenosine.

Yildirim I, Andralojc W, Taghavi A, Baranowski D, Gdaniec Z, Kierzek R Nucleic Acids Res. 2024; 53(1.

PMID: 39711475 PMC: 11724317. DOI: 10.1093/nar/gkae1222.


Dynamic docking of small molecules targeting RNA CUG repeats causing myotonic dystrophy type 1.

Wang K, Riveros I, DeLoye J, Yildirim I Biophys J. 2022; 122(1):180-196.

PMID: 36348626 PMC: 9822796. DOI: 10.1016/j.bpj.2022.11.010.


RNA: Opening New Doors in Medicinal Chemistry, a Special Issue.

Garner A, Djuric S ACS Med Chem Lett. 2021; 12(6):851-853.

PMID: 34141054 PMC: 8201500. DOI: 10.1021/acsmedchemlett.1c00279.

References
1.
Chen C, Sobczak K, Hoskins J, Southall N, Marugan J, Zheng W . Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. Anal Bioanal Chem. 2012; 402(5):1889-98. PMC: 3280409. DOI: 10.1007/s00216-011-5604-0. View

2.
TANEJA K, McCurrach M, Schalling M, Housman D, Singer R . Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol. 1995; 128(6):995-1002. PMC: 2120416. DOI: 10.1083/jcb.128.6.995. View

3.
Childs-Disney J, Wu M, Pushechnikov A, Aminova O, Disney M . A small molecule microarray platform to select RNA internal loop-ligand interactions. ACS Chem Biol. 2007; 2(11):745-54. DOI: 10.1021/cb700174r. View

4.
Rzuczek S, Colgan L, Nakai Y, Cameron M, Furling D, Yasuda R . Precise small-molecule recognition of a toxic CUG RNA repeat expansion. Nat Chem Biol. 2016; 13(2):188-193. PMC: 5290590. DOI: 10.1038/nchembio.2251. View

5.
Kodadek T, Paciaroni N, Balzarini M, Dickson P . Beyond protein binding: recent advances in screening DNA-encoded libraries. Chem Commun (Camb). 2019; 55(89):13330-13341. PMC: 6939232. DOI: 10.1039/c9cc06256d. View